GlassScriptPhysician profile
Navid Kazemi
NPI 1346243367
$19,885.21
in general payments reported to CMS, 2019-2025
32 companies · $5,139 in 2025
The $5,139 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,465 · 2020: $313 · 2021: $3,581 · 2022: $3,045 · 2023: $1,396 · 2024: $1,946 · 2025: $5,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,164 · Travel and Lodging: $3,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,164.17 |
| Travel and Lodging | $3,316.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,551.71 | 2021-2025 | Onyx Frontier, Symplicity G3, Ffrangio |
| Abbott Laboratories | $2,900.41 | 2021-2025 | Xience Skypoint, Dragonfly Opstar, Optis |
| Eli Lilly and Company | $1,909.09 | 2022-2023 | |
| Medtronic Vascular, INC. | $1,878.28 | 2019-2020 | |
| Penumbra, INC. | $1,438.39 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $1,109.59 | 2019-2023 | Verquvo |
| Shockwave Medical, INC | $691.55 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $647.16 | 2022-2024 | Wolverine Coronary Cutting Balloon |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $624.95 | 2019-2025 | Lifevest |
| Angiodynamics, INC. | $445.38 | 2024 | Auryon Laser System 100-120 Vac |
| Amgen INC. | $403.08 | 2025 | Repatha, Repatha |
| Abiomed | $369.26 | 2019-2023 | Impella |
| Impulse Dynamics (USA) INC. | $364.17 | 2023-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $251.96 | 2019-2025 | Camzyos |
| Cvrx, INC. | $195.38 | 2024 | Barostim Neo System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $179.07 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Edwards Lifesciences Corporation | $165.95 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $139.46 | 2022-2023 | |
| Amarin Pharma, INC. | $129.80 | 2019 | |
| Novo Nordisk INC | $117.65 | 2021-2022 | |
| Terumo Medical Corporation | $113.32 | 2019 | |
| Chiesi USA, INC. | $83.64 | 2022 | |
| Bard Peripheral Vascular, INC. | $68.25 | 2023-2025 | Venclose Maven Catheter |
| Alnylam Pharmaceuticals INC. | $33.38 | 2025 | Amvuttra |
| Esperion Therapeutics, INC. | $21.96 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $19.68 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Medtronic USA, INC. | $13.21 | 2019 | |
| Cardiovascular Systems INC. | $4.98 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navid Kazemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.